Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | S100B | P04271 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926474 | 0.83 | POLB (0.48) | CD44CYP3A4TDP1ALDH1A1TSHR | |
| SCHEMBL1425839 | 0.81 | CYP3A4 (0.40) | CD44CYP3A4TDP1ALDH1A1TSHR | |
| SCHEMBL3725651 | 0.81 | POLB (0.40) | CD44CYP3A4TDP1ALDH1A1TSHR | |
| SCHEMBL5812365 | 0.79 | POLB (0.44) | CD44CYP3A4TDP1ALDH1A1TSHR | |
| SCHEMBL16805981 | 0.79 | CYP3A4 (0.43) | CD44CYP3A4TDP1ALDH1A1TSHR | |
| SCHEMBL13070003 | 0.77 | ALDH1A1 (0.39) | CD44CYP3A4TDP1ALDH1A1CASP1 | |
| SCHEMBL24474070 | 0.75 | TDP1 (0.36) | CD44CYP3A4TDP1ALDH1A1TSHR | |
| SCHEMBL404991 | 0.75 | TDP1 (0.36) | CD44CYP3A4TDP1ALDH1A1TSHR | |
| SCHEMBL12224545 | 0.75 | POLB (0.36) | CD44TDP1ALDH1A1POLBCASP1 | |
| SCHEMBL406843 | 0.75 | POLB (0.36) | CD44CYP3A4TDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| EP-3049407-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015044174-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015044174-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| US-6960640-B2 | Composition for optical material | MITSUBISHI GAS CHEMICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040147708-A1 | Composition for optical material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1426392-A1 | COMPOSITION FOR OPTICAL MATERIAL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-0276942-A1 | 6-Beta(substituted)-(S)-hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | CD44 4420/4885CYP3A4 53/4885TDP1 1883/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | CD44 2666/4885CYP3A4 31/4885TDP1 4453/4885 |
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | CD44 4461/4885CYP3A4 285/4885TDP1 456/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | CD44 825/4885CYP3A4 2376/4885TDP1 4213/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CD44 4560/4885CYP3A4 119/4885TDP1 1815/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | CD44 825/4885CYP3A4 2376/4885TDP1 4213/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CD44 4560/4885CYP3A4 119/4885TDP1 1815/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CD44 4560/4885CYP3A4 119/4885TDP1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.